|
Esophageal Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Current literature suggests insufficient accuracy of endoscopic biopsies, EUS, and 18F-FDG PET(-CT) as single modalities for detecting residual disease after nCRT for esophageal cancer.
|
31188203 |
2020 |
|
Esophageal Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Accuracy of <sup>18</sup>F-FDG PET/CT in Predicting Residual Disease After Neoadjuvant Chemoradiotherapy for Esophageal Cancer.
|
30877177 |
2019 |
|
Esophageal Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Prognostic values of mid-radiotherapy <sup>18</sup>F-FDG PET/CT in patients with esophageal cancer.
|
30717809 |
2019 |
|
Esophageal Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Bone Pseudometastasis on 18F-FDG PET in Japanese Patients With Esophageal Cancer.
|
31107756 |
2019 |
|
Esophageal Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
We present a rare case of ectopic PTC within the esophagus with focal FDG activity on FDG PET in a 43-year-old woman who was previously diagnosed as having esophageal cancer based on the endoscopy and PET findings.
|
30394932 |
2019 |
|
Esophageal Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The aim of this prospective study was to evaluate the efficacy of 4DST PET/CT for predicting responses to neoadjuvant therapy in patients with esophageal cancer comparing with FDG PET/CT.
|
30701347 |
2019 |
|
Esophageal Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The aim of this study was to determine the effect of FDG-PET on survival in patients with locally advanced inoperable esophageal cancer.
|
30863993 |
2019 |
|
Esophageal Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Role of intravoxel incoherent motion parameters in gastro-esophageal cancer: relationship with 18F-FDG-PET, CT perfusion and MR perfusion imaging parameters.
|
31496202 |
2019 |
|
Esophageal Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
[<sup>99m</sup>Tc]3PRGD<sub>2</sub> for integrin receptor imaging of esophageal cancer: a comparative study with [<sup>18</sup>F]FDG PET/CT.
|
30392070 |
2019 |
|
Esophageal Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
A Diagnostic Algorithm That Combines Quantitative 18F-FDG PET Parameters and Contrast-Enhanced CT Improves Posttherapeutic Locoregional Restaging and Prognostication of Survival in Patients With Esophageal Cancer.
|
30418211 |
2019 |
|
Esophageal Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Propensity score analysis of 18-FDG PET/CT-enhanced staging in patients undergoing surgery for esophageal cancer.
|
30116837 |
2019 |
|
Esophageal Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Prognostic Value of Volumetric Parameters of Pretreatment 18F-FDG PET/CT in Esophageal Cancer: A Systematic Review and Meta-analysis.
|
30300200 |
2018 |
|
Esophageal Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Overall, 18F-FDG PET/CT have a moderate to low sensitivity and a high to moderate specificity for detection of regional nodal metastasis in esophageal cancer.
|
30622778 |
2018 |
|
Esophageal Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Intratreatment Response Assessment With 18F-FDG PET: Correlation of Semiquantitative PET Features With Pathologic Response of Esophageal Cancer to Neoadjuvant Chemoradiotherapy.
|
30055238 |
2018 |
|
Esophageal Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We determined the value of F-fluorodeoxyglucose positron-emission tomography/computed tomography (FDG PET/CT) for the assessment of preoperative lymph node metastases in patients with esophageal cancer.
|
30558091 |
2018 |
|
Esophageal Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
In this study, we investigated the relationship between the superficial tumor depth of esophageal cancer and the FDG uptake to determine the indications for endoscopic resection (ER).
|
29953743 |
2018 |
|
Esophageal Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
PET-CT studies with 18F-FAMT and 18F-FDG were performed as part of pretreatment work-up in 82 patients with histologically confirmed esophageal cancer.
|
29130979 |
2018 |
|
Esophageal Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The analysis included diagnostic studies reporting on the detection of distant interval metastases with 18F-FDG PET(/CT) in patients with esophageal cancer who received neoadjuvant therapy and both baseline staging and restaging after neoadjuvant therapy with 18F-FDG PET(/CT) imaging.
|
29917073 |
2018 |
|
Esophageal Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The analysis included diagnostic studies describing the accuracy of cervical ultrasonography and integrated F-FDG PET/CT or standalone F-FDG PET and CT for detecting cervical lymph node metastases in patients with esophageal cancer.
|
29672463 |
2018 |
|
Esophageal Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Baseline 18F-FDG PET/CT as predictor of the pathological response to neoadjuvant therapy in esophageal cancer: A retrospective study.
|
30544419 |
2018 |
|
Esophageal Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
This prospective study included 76 patients with histologically proven esophageal cancer who underwent both DW-MRI and F-FDG PET/CT examinations before treatment.
|
29023336 |
2018 |
|
Esophageal Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Relative change in FDG uptake after 14 days of CRT is not associated with DFS in patients with esophageal cancer undergoing neoadjuvant chemoradiotherapy followed by surgery.
|
27001344 |
2017 |
|
Esophageal Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
This study is the first to clarify the FDG-PET performance for EC screening.
|
28487611 |
2017 |
|
Esophageal Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Texture analysis of <sup>18</sup>F-FDG PET/CT to predict tumour response and prognosis of patients with esophageal cancer treated by chemoradiotherapy.
|
27613542 |
2017 |
|
Esophageal Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
A comparative study of target volumes based on <sup>18</sup>F-FDG PET-CT and ten phases of 4DCT for primary thoracic squamous esophageal cancer.
|
28123302 |
2017 |